Photo of Jonathan Karr

Jonathan Karr

  • ASSISTANT PROFESSOR Genetics and Genomic Sciences
Print ProfilePrint Profile


  • Ph.D., Stanford University

  • M.S., Stanford University

  • S.B., Massachusetts Institute of Technology
    Brain & Cognitive Sciences

  • S.B., Massachusetts Institute of Technology



  • 2012 -
    James S. McDonnell Foundation Postdoctoral Fellowship Awards in Studying Complex Systems

  • 2008 -
    National Science Foundation Graduate Fellowship

  • 2008 -
    National Defense Science and Engineering Graduate Fellowship

  • 2008 -
    Stanford University School of Medicine Excellence in Teaching Award

  • 2006 -
    Department of Homeland Security Graduate Fellowship

  • 2006 -
    Stanford University Graduate Fellowship


Our goal is to enable predictive medicine and rational bioengineering. This requires (1) the ability to predict how complex biological behaviors arise from individual molecules and their interactions and (2) the ability to reverse engineer biological systems to have specific phenotypes. Although great progress has been made over the past several decades in the biochemical characterization of individual cells and organisms due to the advent of high-throughput measurement technologies, much work remains to understand and predict how phenotypes emerge. Novel computational techniques which integrate heterogeneous data and mathematics are needed to comprehend the overwhelming complexity of biology. These techniques will not only allow us to predict phenotype from genotype, but ultimately enable us to engineer genotypes to have desired phenotypes.

Under this general theme of understanding how complex phenotypes emerge from the detailed biochemistry inside individual cells, our interests are to:

  • Develop the detailed, comprehensive computational models that will be required for predictive medicine and bioengineering.
  • Use large-scale models to drive biological discovery using experiments guided by model predictions. For example, use models to predict how complex cellular behaviors like growth are controlled at the molecular level and test these predictions experimentally. Investigate which enzymes exert the most control over the rate of cellular growth. Investigate the maximum rate at which an organism can grow. Identify the optimal distribution of gene expression which maximizes cellular growth.
  • Develop novel computational frameworks, algorithms, databases, and analysis tools which enable large-scale hybrid models.
  • Explore new paradigms for collaboratively developing large-scale models.

Recently we developed and validated the first "whole-cell" model of the life cycle of a single cell. Toward this goal we've also developed new methods for model and data integration, model fitting and parameter estimation, and exploratory data analysis.

Please see our website for more information.


Sanghvi JC, Regot S, Carrasco S, Karr JR, Gutschow MV, Bolival B, Covert MW. Accelerated discovery via a whole-cell model. Nature methods 2013 Dec; 10(12).

Lee R, Karr JR, Covert MW. WholeCellViz: data visualization for whole-cell models. BMC bioinformatics 2013; 14.

Purcell O, Jain B, Karr JR, Covert MW, Lu TK. Towards a whole-cell modeling approach for synthetic biology. Chaos 2013 Jun; 23(2).

Karr JR, Sanghvi JC, Macklin DN, Arora A, Covert MW. WholeCellKB: model organism databases for comprehensive whole-cell models. Nucleic acids research 2013 Jan; 41(Database issue).

Karr JR, Sanghvi JC, Macklin DN, Gutschow MV, Jacobs JM, Bolival B, Assad-Garcia N, Glass JI, Covert MW. A whole-cell computational model predicts phenotype from genotype. Cell 2012 Jul; 150(2).

Covert MW, Xiao N, Chen TJ, Karr JR. Integrating metabolic, transcriptional regulatory and signal transduction models in Escherichia coli. Bioinformatics 2008 Sep; 24(18).

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Karr did not report having any of the following types of financial relationships with industry during 2012 and/or 2013: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at Patients may wish to ask their physician about the activities they perform for companies.

Edit profile in Sinai Central


Icahn Medical Institute Floor 3 Room 70, Desk #1
1425 Madison Avenue
New York, NY 10029